Esperion Therapeutics Inc. (ESPR) 宣布,已与Alkem Laboratories就后者申请仿制Nexletol和Nexlizet的简略新药申请(ANDA)所引发的专利诉讼达成和解协议。该协议成功解决了由Esperion提起的专利法律纠纷。
Esperion Therapeutics Inc. (ESPR) 宣布,已与Alkem Laboratories就后者申请仿制Nexletol和Nexlizet的简略新药申请(ANDA)所引发的专利诉讼达成和解协议。该协议成功解决了由Esperion提起的专利法律纠纷。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.